Shares of Lumos Pharma, Inc. (NASDAQ:LUMO) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $31.00.

Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Lumos Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, January 13th. Cantor Fitzgerald assumed coverage on Lumos Pharma in a research report on Wednesday, December 2nd. They set an “overweight” rating and a $32.00 price target on the stock. Finally, HC Wainwright raised their price target on Lumos Pharma from $33.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, November 23rd.

NASDAQ:LUMO traded down $0.95 during trading hours on Tuesday, hitting $14.95. 431 shares of the company’s stock traded hands, compared to its average volume of 37,699. The firm has a market cap of $124.04 million, a P/E ratio of -5.85 and a beta of 1.69. Lumos Pharma has a 52 week low of $6.74 and a 52 week high of $36.72. The business’s fifty day simple moving average is $19.49 and its two-hundred day simple moving average is $17.38.

In other news, major shareholder James E. Flynn sold 29,039 shares of Lumos Pharma stock in a transaction dated Wednesday, January 6th. The stock was sold at an average price of $22.48, for a total value of $652,796.72. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder James E. Flynn sold 106,512 shares of Lumos Pharma stock in a transaction dated Friday, January 8th. The stock was sold at an average price of $22.31, for a total value of $2,376,282.72. The disclosure for this sale can be found here. Company insiders own 15.90% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. West Financial Advisors LLC purchased a new position in shares of Lumos Pharma in the fourth quarter worth about $28,000. One68 Global Capital LLC purchased a new position in shares of Lumos Pharma in the fourth quarter worth about $209,000. Foster Group Inc. purchased a new position in shares of Lumos Pharma in the fourth quarter worth about $221,000. Verition Fund Management LLC purchased a new position in shares of Lumos Pharma in the fourth quarter worth about $351,000. Finally, Northern Trust Corp increased its holdings in shares of Lumos Pharma by 292.0% in the fourth quarter. Northern Trust Corp now owns 12,081 shares of the company’s stock worth $432,000 after buying an additional 8,999 shares during the period. Hedge funds and other institutional investors own 43.79% of the company’s stock.

About Lumos Pharma

Lumos Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency.

Further Reading: What are catch-up contributions?

Analyst Recommendations for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.